Dihydromyricetin suppresses the proliferation of hepatocellular carcinoma cells by inducing G2/M arrest through the Chk1/Chk2/Cdc25C pathway

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2467-2475

  Huang, Haili ^a   Hu, Min ^a   Zhao, Rui ^b   Li, Peng ^a   Li, Mingyi ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cdk1 cylin B1 complex; Dihydromyricetin; G2 M arrest; Hepatocellular carcinoma

Indexed keywords

AMPELOPSIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; MYRICETIN; PROTEIN CDC25C; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME INACTIVATION; G2 PHASE CELL CYCLE CHECKPOINT; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; LIVER CELL CARCINOMA; PRIORITY JOURNAL;

CARCINOMA, HEPATOCELLULAR; CDC25 PHOSPHATASES; CELL PROLIFERATION; CHECKPOINT KINASE 2; FLAVONOLS; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84885047377     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2705     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
2. Stewart ZA, Westfall MD and Pietenpol JA: Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci 24: 139-145, 2003.
3. Huang WW, Ko SW, Tsai HY, et al: Cantharidin induces G2/M phase arrest and apoptosis in human colorectal cancer colo 205 cells through inhibition of CDK1 activity and caspase-dependent signaling pathways. Int J Oncol 38: 1067-1073, 2011.
4. Visanji JM, Thompson DG and Padfield PJ: Induction of G2/M phase cell cycle arrest by carnosol and carnosic acid is associated with alteration of cyclin A and cyclin B1 levels. Cancer Lett 237: 130-136, 2006.
5. Parker LL and Piwnica-Worms H: Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science 257: 1955-1957, 1992.
6. Ruiz EJ, Vilar M and Nebreda AR: A two-step inactivation mechanism of Myt1 ensures CDK1/cyclin B activation and meiosis I entry. Curr Biol 20: 717-723, 2010.
7. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS and Piwnica-Worms H: Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277: 1501-1505, 1997.
8. Ahn J and Prives C: Checkpoint kinase 2 (Chk2) monomers or dimers phosphorylate Cdc25C after DNA damage regardless of threonine 68 phosphorylation. J Biol Chem 277: 48418-48426, 2002.
9. Turowski P, Franckhauser C, Morris MC, Vaglio P, Fernandez A and Lamb NJ: Functional cdc25C dual-specificity phosphatase is required for S-phase entry in human cells. Mol Biol Cell 14: 2984-2998, 2003.
10. Choi YH, Lee WH, Park KY and Zhang L: p53-independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 91: 164-173, 2000.
11. Rief N, Herges H, Prowald A, Gotz C and Montenarh M: Binding of the growth suppressor p53 protein to the cell cycle regulator phosphatase cdc25C. Int J Oncol 17: 189-195, 2000.
12. St Clair S, Giono L, Varmeh-Ziaie S, et al: DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol Cell 16: 725-736, 2004.
13. Hirao A, Kong YY, Matsuoka S, et al: DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 287: 1824-1827, 2000.
14. Ye R, Bodero A, Zhou BB, Khanna KK, Lavin MF and Lees-Miller SP: The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner. J Biol Chem 276: 4828-4833, 2001.
15. Canman CE, Lim DS, Cimprich KA, et al: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281: 1677-1679, 1998.
16. Banin S, Moyal L, Shieh S, et al: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281: 1674-1677, 1998.
17. Dalal SN, Schweitzer CM, Gan J and DeCaprio JA: Cytoplasmic localization of human cdc25C during interphase requires an intact 14-3-3 binding site. Mol Cell Biol 19: 4465-4479, 1999.
18. Graves PR, Lovly CM, Uy GL and Piwnica-Worms H: Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding. Oncogene 20: 1839-1851, 2001.
19. Savitsky PA and Finkel T: Redox regulation of Cdc25C. J Biol Chem 277: 20535-20540, 2002.
20. Bulavin DV, Demidenko ZN, Phillips C, Moody SA and Fornace AJ Jr: Phosphorylation of Xenopus Cdc25C at Ser285 interferes with ability to activate a DNA damage replication checkpoint in pre-midblastula embryos. Cell Cycle 2: 263-266, 2003.
21. Perdiguero E and Nebreda AR: Regulation of Cdc25C activity during the meiotic G2/M transition. Cell Cycle 3: 733-737, 2004.
22. Tyagi A, Singh RP, Agarwal C, Siriwardana S, Sclafani RA and Agarwal R: Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells. Carcinogenesis 26: 1978-1987, 2005.
23. Zeng S, Luo GQ and Liu DY: The chemotaxis effect of ampelopsin on the immunocytes. Zhong Yao Cai 29: 260-262, 2006 (In Chinese).
24. He G, Du F, Yang W, Pei G and Zhu Y: Effects of tengcha flavonoids on scavenging oxygen free radicals and inhibiting lipid-peroxidation. Zhong Yao Cai 26: 338-340, 2003 (In Chinese).
25. Murakami T, Miyakoshi M, Araho D, et al: Hepatoprotective activity of tocha, the stems and leaves of Ampelopsis grossedentata, and ampelopsin. Biofactors 21: 175-178, 2004.
26. Ni F, Gong Y, Li L, Abdolmaleky HM and Zhou JR: Flavonoid ampelopsin inhibits the growth and metastasis of prostate cancer in vitro and in mice. PLoS One 7: e38802, 2012.
27. Zeng S, Liu D, Ye Y, Wang L and Wang W: Antitumor effects of ampelopsin on human lung cancer GLC-82 implanted in nude mice. Zhong Yao Cai 27: 842-845, 2004 (In Chinese).
28. Liu D and Luo M: Study on inhibitory effect of ampelopsin on melanoma by serologic pharmacological method. Zhong Yao Cai 24: 348-350, 2001 (In Chinese).
29. Liu DY, Zheng HQ and Luo GQ: Effects of ampelopsin on invasion and metastasis of B16 mouse melanoma in vivo and in vitro. Zhongguo Zhong Yao Za Zhi 28: 957-961, 2003 (In Chinese).
30. Luo GQ, Zeng S and Liu DY: Inhibitory effects of ampelopsin on angiogenesis. Zhong Yao Cai 29: 146-150, 2006 (In Chinese).
31. Ye J, Zheng Y and Liu D: Reversal effect and its mechanism of ampelopsin on multidrug resistance in K562/ADR cells. Zhongguo Zhong Yao Za Zhi 34: 761-765, 2009 (In Chinese).
32. Nurse P: Universal control mechanism regulating onset of M-phase. Nature 344: 503-508, 1990.
33. Zhong ZX, Qin JP, Zhou GF and Chen XF: Experimental studies of hypoglycemic action on total flavone of Ampelopsis grossedentata from Guangxi. Zhongguo Zhong Yao Za Zhi 27: 687-689, 2002 (In Chinese).
34. Lukas J, Bartkova J, Rohde M, Strauss M and Bartek J: Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol 15: 2600-2611, 1995.
35. Wang Z, Xie Y, Zhang L, et al: Migratory localization of cyclin D2-Cdk4 complex suggests a spatial regulation of the G1-S transition. Cell Struct Funct 33: 171-183, 2008.
36. Goldstone S, Pavey S, Forrest A, Sinnamon J and Gabrielli B: Cdc25-dependent activation of cyclin A/cdk2 is blocked in G2 phase arrested cells independently of ATM/ATR. Oncogene 20: 921-932, 2001.
37. Galaktionov K, Lee AK, Eckstein J, et al: CDC25 phosphatases as potential human oncogenes. Science 269: 1575-1577, 1995.
38. Karlsson C, Katich S, Hagting A, Hoffmann I and Pines J: Cdc25B and Cdc25C differ markedly in their properties as initiators of mitosis. J Cell Biol 146: 573-584, 1999.
39. Li J and Stern DF: Regulation of CHK2 by DNA-dependent protein kinase. J Biol Chem 280: 12041-12050, 2005.
40. Peng A and Chen PL: NFBD1, like 53BP1, is an early and redundant transducer mediating Chk2 phosphorylation in response to DNA damage. J Biol Chem 278: 8873-8876, 2003.